



HHS Public Access

Author manuscript

Int J Diabetes Res. Author manuscript; available in PMC 2017 September 19.

Published in final edited form as:

Int J Diabetes Res. 2016 ; 5(5): 92–101.

Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions

Jorge R. Miranda-Massari^{1,2,3,*}, José R. Rodríguez-Gómez^{4,5}, Michael J. González⁶, Carlos Cidre⁷, Jorge Duconge⁸, Heriberto Marín⁹, Kazuko Grace², and Howard L. McLeod^{10,11}

¹Dept. of Pharmacy Practice, School of Pharmacy, Medical Sciences Campus, UPR, San Juan, PR

²Metabolic Correction Institute, San Juan, PR

³EDP University, San Juan Campus, PR

⁴University of Puerto Rico, Rio Piedras Campus, Faculty of Social Sciences, Department of General Social Sciences, San Juan, PR

⁵Carlos Albizu University, San Juan Campus, San Juan, PR

⁶Dept. of Human Development, School of Public Health, Medical Sciences Campus, UPR, San Juan, PR

⁷Dr. Carlos Cidre's Clinical Practice, Manati, PR

⁸Dept. of Basic Science, School of Pharmacy, Medical Sciences Campus, UPR, San Juan, PR

⁹Dept. of Administration of Health Services, School of Public Health, Medical Sciences Campus, UPR, San Juan, PR

¹⁰Medical Director, The DeBartolo Family Personalized Medicine Institute

¹¹Senior Member, Division of Population Sciences, Moffitt Cancer Center, Tampa, FL, USA

Abstract

Diabetes is a leading cause of mortality and morbidity worldwide. Diabetes complications produce profound impact on patient's quality of life and represent very significant economic cost to patients, their family, the government and society as a whole. Metabolic correction has been proposed as an efficient method to improve clinical outcomes and reduce costs in diabetes. Metabolic correction is a concept that supports health maintenance and promotes the healing processes by improving the body's biochemical-physiological mechanisms. This is done by helping activate the metabolic enzymes necessary to facilitate key physiological pathways. A group of 50 patients followed a simple metabolic correction strategy based on hydration, diet, and magnesium supplementation during a 6 months period. Outcomes measures included laboratory testing, anthropometric measures and medication use including its related costs. Patients had an average weight loss of 9.4 lbs (↓5.0%) from baseline at month 3 and 12 lbs (↓6.4%) at month 6. Waist circumference decreased on average 3.7 inches (↓9.0%) from baseline at month 3 and had

*Corresponding author: jorge.miranda2@upr.edu (Jorge R. Miranda-Massari).

further decrease to 5.5 inches (\downarrow 13.4%) from baseline at month 6. Laboratory testing of average triglycerides decreased from a baseline of 156.9 to 116.7 (\downarrow 25.6%) at month 3 and maintained a reduction of \downarrow 24.2% by month 6. Total cholesterol concentration decreased from a baseline of 181.1 mg/dL to 173.9 (\downarrow 4.0%) in month 3 and to 171.1 (\downarrow 5.5%) at month 6. Average HgA1c decreased from baseline of 7.17 to 6.52 (\downarrow 9.1%) at month 3 and maintained 6.52 at months 6. The atherogenic index decreased from 4.18 at baseline to 3.85 at month 3 (\downarrow 7.9%) and then 3.47 (17.0%) at month 6. Medication use and cost was quantified in various ways. The average baseline monthly diabetes medication cost per patient of \$124.10 was reduced to \$ 78.23 (\downarrow 36.7% reduction) at month 3 and to \$62.80 (\downarrow 49.4% reduction) at month 6. A simple and well structured metabolic correction program that includes a significant educational component, dietary modifications and dietary supplement intake was able to maintain or improve vital signs, anthropometric and laboratory measurements that correlate with improved clinical diabetes and cardiovascular health. This outcome was achieved while decreasing the use medications at month 3 and 6 at significant cost savings.

Keywords

Diabetes; Metabolic Correction; Diet; Magnesium; Diabetes care cost; Cost reduction; Magnesium supplementation

1. Introduction

The number of patients with Diabetes Mellitus Type 2 (DM2) has continued to grow worldwide steadily making DM2 a serious epidemic of potentially catastrophic proportions. [1–3] Aside from the health implications and inherent life difficulties related to having diabetes the global DM2 epidemic is also skyrocketing the disease management costs. In some developing countries, DM2 threatens to bankrupt the health agencies as pharmaceutical medication prices have continued to outgrow the inflationary trend. [4, 5] Economists at the Centers for Disease Control and Prevention (CDC) of the United States have reported that the cost of having diabetes has doubled in just two decades. [6] Besides the personal suffering, loss of productivity and negative social implications of DM2, the fact appears to be that DM2 together with its closely related companion obesity foretells of a global public health crisis that threatens the economies, the social structure and the public health agencies of all nations. [2, 7–13]

The DM2 statistics are alarming and the future projections are gloomy. The International Diabetes Federation (IDF) revealed in a press release in 2011 revealed that the number of people living with diabetes was expected to rise from 366 million in 2011 to 552 million by 2030 when one in every ten people was expected to be diabetic, if no urgent action was taken. [14, 15]

Attempts at managing DM2's hyperglycemia with intensive oral or injected hypoglycemic medication have proven dismal as they increased mortality for the diabetic patients aside from being exceedingly costly. [16–19] There is some evidence that achieving a reduction in the DM2 patient's dosage needs for exogenous insulin can reduce all mortality cause, cardiovascular events and the incidence of cancer. [20–22] Furthermore, the intensive

glucose control has been focused on hypoglycemic medication that has been emphasized during the last decades seems to be the main cause of a growing wave of diabetic hypoglycemic events. Hospital admission rates for diabetic hypoglycemia now exceed those for hyperglycemia among older adults adding more financial burdens to an already overtaxed health system. [23] Diabetic patients are now more likely to experience adverse events related to overtreatment of diabetes mellitus. [24] Meanwhile the costs associated with hospitalization for patients with DM2 accounts for half of all health care expenditures for this disease. [25–27].

RATIONALE OF METABOLIC CORRECTION THERAPY

The “metabolic correction” concept is a clinical strategy that addresses the root biochemical causes of disease by providing the body with quality nutrition of a low glycemic load (LGL), while also supplying vital hydration and the necessary micronutrients that potentiate metabolism and mitochondrial energy production. The metabolic correction paradigm, postulates that most sickness are related to an energetic deficiency that affects the body’s natural ability to sustain its life systems and its natural homeostatic balance. [28–29]. From this perspective DM2 is just another of the many ways in which the basic energy producing capacity of the body has been compromised, thus creating DM2 which is a metabolic disorder that negatively affects health from metabolic consequences of elevated glucose and many other metabolic disturbances. Within the realm of the metabolic correction concept, any effort made to improve the body’s quantity or quality of energy production is considered valuable. This includes taking into consideration a patient’s individual hereditary differences that could potentially affect his body’s metabolic efficiency and its energy production capacity thus influencing his diabetic control and his obesity propensity. These hereditary differences include metabolic genetic variables like having a body that is either of sympathetic or parasympathetic central nervous system dominance propensities. Some researchers have documented that individual adjustment to the patient’s selection of food according to their individual sympathetic or parasympathetic dominance propensity maintains an adequate metabolic energy production rate. [30, 31] The autonomic nervous system has a substantial influence over DM2 control therefore; it is an important therapeutic consideration. [32, 33]

The previous concepts could be provocatively new or even uncomfortably uncommon so the sole proof as to the workability of the “metabolic correction” paradigm or its tenets should rest only in its measurable clinical results. To prove its value any novel clinical protocol concept needs clinical confirmation. This information would ideally result not only in a valid scientific contribution to “evidence based medicine” but also in an even more desirable goal of “result based medicine”.

2. Methods

An educational metabolic restorative method based on the “metabolic correction” concept and coined as the “Metabolic Restorative Technology Medical Protocol” (MRT-MD) had first been tested on a previous study with 25 DM2 patients for a period for 13 weeks’ as a prospective cohort study under medical supervision. [34] The MRT-MD protocol had

evolved out of the practical experiences accumulated with 30,642 weight loss patients at a private weight loss clinic by 2008 and increased to 92,620 by 2015 where many of the obese DM2 patients had reported significant improvements in their diabetic control after utilizing the MRT-MD protocol. [34, 35] The use of this protocol had showed statistically significant benefits in DM2 weight loss (WL), in reducing lipids, in lowering fasting blood glucose (FBG) and in reducing waist circumference (WC) while also improving DM2 control.

An interesting finding of the first study was that 21 of the 25 DM2 patients had medication dosage reduction ordered by their physicians in one or more of their chronic medications. This became an important finding because it indicated that any positive outcomes achieved by this protocol were not a result of new medications or dosage increase, but occurred despite a reduction in their medication. [34] The calculation on cost savings by medication reductions were not performed in our previous publication on 25 DM2 patients as it was not part of the scope of the study. However the observation that 21 of the 25 patients had reported medication reductions in both diabetic (insulin and oral hypoglycemic agents) and non-diabetic medications (antihypertensives, antilipidemics, etc.) suggest that MRT-MD protocol has a potential for achieving medical expense reductions. This study provided the basis for larger second longitudinal cohort study with a design that would include per patient medication cost both clinical and biochemical analysis during a 6-month period.

EDUCATING THE DM2 PATIENT TO FOSTER PATIENT RESPONSIBILITY

The National Center for Education measured the health literacy in the United States and published the results in their 2003 report. [36] This comprehensive report shows that only 12% (1 in 8) of the American population are proficient at understanding their own health condition and that means that 88% of the population varies from total ignorance to only having a basic understanding of their health condition. This analysis and its statistical data seemed to point out that there is insufficient patient education if we are ever to reverse the DM2 medical complications and the financial burdens they carry.

There have been many previous attempts to educate DM2 patients in order to control hyperglycemia and reduce medical complications and medical expenses with some limited or modest success. [37–40]. The MRT-MD protocol seems to be a promising fresh educational approach as it teaches several unique metabolic enhancing strategies that had previously showed statistically significant results including an unusually high patient satisfaction index that translated into weight loss, more energy, better sleep quality and a generally increased adherence to the new DM2 lifestyle. [34]

REDUCING DM2 HYPERGLYCEMIA

The MRT-MD protocol is a novel educational approach that specifically teaches DM2 patients how to reduce or avoid hyperglycemic events by educating them on the glycemetic effect that each different food type has. This is achieved with the help of the 3×1 Diet ® that simplifies a diabetic patient's food selection and combining options without a need for counting calories, diabetic food exchange lists, weighting grams or other hard to understand or limiting nutritional plans. [34] It also teaches DM2 patients to monitor their postprandial glucose regularly to allow them to learn from the effects of their own food choices and the

resulting glycemic levels. [41–44] As other complementary individualized metabolic correction factors like efficient hydration and autonomic nervous system predominance differentiation are taken into consideration some promising results have been experienced with DM2 patients. [33, 34, 45]

Reducing hyperglycemia is a mayor goal of the MRT-MD protocol. The LGL 3×1 Diet® had previously proven effective at achieving lower postprandial glucose averages for DM2 patients and a reduce their A1c Hemoglobin. [34] The MRT-MD protocol utilizes multiple graphical illustrations with suggestions and examples of possible meals, breakfasts and food combinations that would result in lower average glucose level that are conducive to both weight loss and lower glycemic averages. [46] In our estimation, lower postprandial glycemic averages would also translate into better DM2 control and less hypoglycemic medication needs.

WEIGHT LOSS (WL), WAIST CIRCUMFERENCE (WC) & BMI REDUCTIONS

An estimated 85% of all DM2 patients are overweight or obese so one of the goals of the MRT-MD protocol is to help diabetic patients reduce their weight. Most DM2 patients are overweight and more than half are obese. [9] Achieving reductions of WC in overweight or obese DM2 patients has been found to have significant cardiovascular risk reduction benefits. [47–49] Meanwhile cardiovascular diseases (CVDs) remain the leading cause of both disability and mortality amongst diabetic patients. [50, 51] Furthermore, approximately 80% of all deaths and most hospitalizations in DM2 patients are attributable to cardiovascular causes [52]. It has been found that even moderate WL will improve DM2 control while reducing medical management and medication costs [53–56] Thus, DM2 patients should do their best to reduce BW, BMI and WC as it could result in not just improved health and energy for the patients but could also conceivably result in reduced total medical expenses for both diabetes and non-diabetic related conditions.

MAGNESIUM SUPPLEMENTATION FOR DM2 PATIENTS

Previous clinical experience of the MRT-MD protocol has demonstrated that neither glucose control in patients with DM2, nor its insulin resistance or their related conditions like hypertension can be consistently improved if there is a magnesium deficiency or insufficiency present. Magnesium deficiency appears to be exceptionally common within the DM2, obese and overweight populations probably because of poor dietary habits. The 2005–2006 National Health and Nutrition Examination Survey (NHANES) revealed that at least half of the U.S. population had inadequate intakes of magnesium. [57–58] DM2 has been closely associated with magnesium deficiencies that aggravate insulin resistance and its associated metabolic syndrome. [59–61] The MRT-MD protocol practitioners have found it of benefit to supplement DM2 patients with magnesium on a “bowel tolerance” dosage mode. There are abundant references that support magnesium supplementation for a large portion of the population but especially for DM2 patients. [60, 62–64]

With DM2 patients, the sympathetic nervous system relaxation effects caused by magnesium also seems to help in improving sleep quality. Since sleep loss and poor sleep quality have both been found to aggravate insulin resistance while also promoting hyperglycemia, obesity

and hypertension magnesium supplementation is presumed to improve the DM2 patient outcomes. [62, 65–72] DM2 patients have a high incidence of hypertension and in this respect; magnesium supplementation could be beneficial. [73–75] Finally, magnesium supplementation seems to have some potential in reducing medication needs thereby reducing medical management costs. [59, 63–64, 76–78]

3. Study Design and Scope

We followed prospectively 50 patients with DM2 in a longitudinal 6 months (26 weeks) cohort study with two cut off points at 3 months (13 weeks) and at 6 months (26 weeks) for comparison purposes. The study recorded anthropometric measurements of BW, WC, BMI as well as each patient's TG, CH, LDL, HDL, A1c levels at the start and at each of the two cut-off points at 3 months and 6 months' time. The study calculated the atherogenic index of plasma (AIP= $\log \text{ TG/HDL mmol/l}$) as it predicts the risk of development of atherosclerosis in diabetic patients. [79] Studies have shown that serum triglyceride level is an independent determinant of cardiovascular risk. [80–81]

CALCULATING POSSIBLE MEDICAL COST REDUCTIONS

To assess any possible medication cost reductions that could be achieved as a result of the clinical application of the MRT-MD educational protocol detailed records were kept on each DM2 patient's medication dosages and their average costs per patient plus the type of medication (diabetic, non-diabetic) that was being consumed each participant. Average medication costs per dosage of all medications being consumed by the participants were calculated at each of the study's two cut-off points (3 months and 6 months) using the lower price quoted by the GOODRX medicine cost calculating software available at www.goodrx.com provided by Goodrx Inc. in California, USA.

A group of patients with DM2 underwent an educational program, with the help of the audio-visual graphics developed by the MRT-MD protocol practitioners. This program is designed to achieve a balance of protein, carbohydrate and fats at each of its three main meals with an emphasis in not exceeding a certain portion of their food plate with a certain amount of HGL carbohydrates. (82–88) Initially, as the patients learned to implement their new lifestyle and their 3×1 Diet® they received follow up every 2 weeks during the first 3 months. Then they were only monitored once a month during the last 4 to 6 months of the study when the anthropometric results of the first 3 months had shown that each participant had settled into the new lifestyle routine and was able to sustain it on his own.

4. Study Results

Fifty patients with DM2 participated in the study (29 females and 21 males) for a period of 6 months. Data recollection included baseline measurements and cut off points at 3 and 6 months. The study anthropometric and health parameters results are summarized in figures 1 and 2 below:

MEDICINE NEEDS AND COST CHANGES

On the hypothetical possibility that through its metabolic correction effects the MRT-MD educational protocol could achieve a reduction of the DM2 patient's medication needs and medication costs the researchers were pleasantly surprised with the study results. As suspected, the MRT-MD protocol reduced medication needs both for diabetes hypoglycemic medications (i.e., metformin, sulfonylureas, insulin) as well as for other non-diabetes medications (hypertension, neuropathy, thyroid, etc.) although the largest cost reduction was in the diabetic medications category. Figure 3 and Table 1 below describe cost reductions per patient and in the study group. Oral diabetes medications included glimepiride, glipizide, glyburide, metformin-sitagliptin, metformin, saxagliptin, linagliptin and linagliptin. Insulins used were Novolin 70/30 and Humulin N. Non-diabetes medication used were mostly various kinds of antihypertensives, antilipidemics, a proton pump inhibitor, methotrexate as antiinflammatory, gabapentin or pregabalin for neuropathic pain, sertraline or bupropion as antidepressant.

5. Statistical Analysis

A 2 tailed paired T test was conducted to determine if there are differences between the parameters values measured at baseline compared to the values measured at 3 and 6 months.

We found significant differences between the values of several parameters. Weight, BMI, Waist, A1c and TC all had statistical significant differences between baseline and both, 3 months and between baseline and 6 months. We also found statistically significant difference for HDL when comparing baseline to values at 6 months but not with values at 3 months. Also, found statistically significant difference for atherogenic index when comparing baseline to values at 6 months but not with values at 3 months. With regard to blood pressure, we found that measurements at baseline, were not significantly different than those at month 3; however, values achieved a statistically significant difference at month 6.

Another very important observation was a statistically significant reduction in the use of all categories of medications including insulin, oral hypoglycemics and non-diabetes medications.

The percentual cost reduction of medication was most dramatic in the oral hypoglycemic agents. Cost reduction in this category at month 3 was 57.9% and it reached 69.7% by month 6. However, since insulin is the most expensive medication the impact of insulin reduction had a greater weight in the total cost reduction.

The statistical analysis of cost reductions related to decrease in medication is as follows (see Tables 9 & 10 for diabetic medications and non-diabetic medications respectively).

The statistical analysis of cost reductions related to decrease in medication is as follows:

From baseline (period 1) to period 2, (3 months) the cost reduction in diabetes medications (Includes Insulin and other oral Hypoglycemic agents), was significant 45.57, ($p < .03$), First period (baseline) to third period (6 months) cost reduction was significant, 96.48 ($P < .01$). However, 3 months versus 6 months cost reduction was not significant 50.90 ($P < .138$).

Non-diabetic medications also demonstrate a significant decrease. The statistical analysis of cost reductions related to decrease in non diabetic medications is as follows: From baseline (period 1) to period 2 (3 months) the cost reduction in non diabetes medications was significant 45.57, ($p<.03$), First period (baseline) to third period (6 months) cost reduction was significant, 96.48 ($P<.01$). However, 3 months versus 6 months cost reduction was not significant 50.90 ($P<.138$). The main impact for change in non diabetic medications came from the baseline period to 3 and 6 months period.

6. Discussion

Metabolic correction is a concept that can encompass from a very comprehensive set of evaluations and interventions to a relatively simple strategy. The interventions in this study were limited to a simple nutritional/hydration guideline and magnesium supplementation reinforced by a well-structured educational tool. The results from the metabolic correction protocol resulted in statistically significant and beneficial changes in anthropometric measurements and laboratory values (Weight, BMI, Waist, A1c and TC).

The benefits obtained by the intervention at month 3 where sustained or improved by month 6.

One important consideration is that the implementation of the metabolic correction protocol over a 6 months period lead to significant improvements in several anthropometric and laboratory parameters while reducing the use of medications. The reduction in the use of medication occurred in all medications including insulin, oral hypoglycemics and non-diabetes medications.

Non-diabetes medication included antihypertensive, diuretics, hypocholesterolemia agents, neuropathic pain medication, proton pump inhibitor, antidepressants and benzodiazepines. Reducing the dose of medications has the benefit of reducing both the cost of the medication as well as its associated adverse effects.

In addition, very significant reductions in the use and cost of medication were documented during the study period. With regard to diabetes medications, the average monthly cost per patient at baseline was \$124.10. This cost was reduced to \$78.53 ($\downarrow 36.7\%$) at month 3 and further decrease to \$62.80 ($\downarrow 49.4\%$). With regard to non-diabetic medications, the average monthly cost per patient at baseline was \$31.41. This cost was reduced to \$28.18 ($\downarrow 10.3\%$) at month 3 and further decrease to \$27.62 ($\downarrow 12.1\%$).

Implementation of metabolic correction produced conditions that allowed reductions in insulin doses. The monthly cost of insulin at baseline for the 11 patients in the study was \$4,536.12. This cost was reduced to \$3,219.26 ($\downarrow 29.0\%$) at month 3 and further decrease to \$2,633.72 ($\downarrow 41.9\%$) at month 6. The average monthly cost per patient in all medications at baseline was \$155.51. This cost decreased to \$106.71 ($\downarrow 31.4\%$) at month 3 and further decrease to \$90.43 ($\downarrow 41.9\%$) at month 6.

Achieving good clinical outcomes with less medication not only produces the direct cost savings of decrease medication costs, but decrease medication use will reduce drug related

morbidity and mortality. Drug induced morbidity and mortality is due to drug-induced nutrient depletion, mitochondrial dysfunction and other pharmacological and genetic idiosyncrasies. Drug related morbidity and mortality has been shown to have very significant costs (89–90).

To understand the impact on the health system and the individual we clarify the distribution of the medication cost coverage. In this population studied the main payer for the medications was Medicare comprising 90% patients followed by private insurance in 10% the patients and none out of pocket.

Before this study, we developed a theoretical model explaining how metabolic correction can contribute to not only improve clinical outcomes, but also reduce healthcare costs. In this model, which is being prepared for publication, we proposed that metabolic correction has the potential of reducing complications of the disease by addressing its underlying causes. We also proposed that by using metabolic correction, medication use can be reduced, and therefore, the associated cost. In addition, in that research we also produced estimates of the cost reduction by implementing metabolic correction. It appears that the implementation of metabolic correction has significant potential to produce good clinical results and at the same time produce significant cost savings. More research is needed in order to define the extent of the clinical benefits as well as several important variables decreasing costs and the economic impact of this intervention.

7. Conclusions

This simple and well-structured metabolic correction program that includes a significant educational component, structured hydration, dietary modifications and dietary supplement intake was able to maintain and/or improve diabetic patient anthropometric measurements and laboratory measurements that correlate with good clinical outcomes in diabetes and cardiovascular health. Therefore, if these benefits can be sustained over a prolonged period, it is expected that patients can experience corresponding decrease in health risks complications accompanied by a reduction in healthcare cost.

In addition to the expected decrease in health risks, by achieving improvements in anthropometric and laboratory values, the Metabolic Correction intervention demonstrated significant decrease in costs due to reduction in medication use. Considering the cumulative drug toxicities, its possible that the cost saving of the long term use of metabolic correction could be greater than in the short term. Longer studies are needed to evaluate if the clinical benefits observed at 3–6 months can be sustained over a longer period. In addition, medication use, hospitalizations and overall cost of patient care should be evaluated over a prolonged period.

References

1. WHO. Country and regional data on diabetes. World Health Organization. WHO; 2015. from <http://www.who.int/diabetes/facts/en/> [Retrieved Nov 8, 2015]
2. Hu Frank B. Globalization of Diabetes. *Diabetes Care*. 2011 Jun; 34(6):1249–1257. [PubMed: 21617109]

3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature*. 2001 Dec 13; 414(6865):782–7. [PubMed: 11742409]
4. CMS. National Health Expenditure Projections, 2014–24: Spending Growth Faster Than Recent Trends. *Health Affairs CMS*. 2015 Jul; 34(8):1407–1417.
5. WHO Medicine Prices. New WHO report shows that transparency and cooperation help to reduce high prices for new medicines. Copenhagen: WHO; 2015. from <http://0x9.me/DqJKO> [Retrieved Nov 8, 2015]
6. Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW. Change in Medical Spending Attributable to Diabetes: National Data From 1987 to 2011. *Diabetes Care*. 2015 Jan 15.
7. Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. *Am J Prev Med*. 2013 Sep; 45(3):253–61. [PubMed: 23953350]
8. ADA Diabetes Costs. Economic Costs of Diabetes in the U. S. in 2012. *Diabetes Care*. 2013 Apr; 36(4):1033–1046. [PubMed: 23468086]
9. Centers for Disease Control and Prevention. Prevalence of Overweight and Obesity Among Adults with Diagnosed Diabetes - United States, 1988--1994 and 1999–2002. *Morbidity and Mortality Weekly Report (MMWR)*. 2013; 62(28)
10. Nat. Diabetes Stat. National Diabetes Statistics. 2011; 2011 [Retrieved Sept 15, 2013] from <http://diabetes.niddk.nih.gov/dm/pubs/statistics>.
11. U.S. Dept. of Health and Human Services. [Retrieved Sept 19, 2013] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). 2012 Jun. from National Diabetes Information Clearinghouse (NDIC): <http://diabetes.niddk.nih.gov/dm/pubs/sup/>
12. Kelly T, et al. Global burden of obesity in 2005 and projections to 2030. *Int J Obes (Lond)*. 2008 Sep; 32(9):1431–7. [PubMed: 18607383]
13. Ohlson LO, Larsson B, Svärdsudd K, Welin L, Eriksson H, Wilhelmsen L, Björntorp P, Tibblin G. The Influence of Body Fat Distribution on the Incidence of Diabetes Mellitus: 13.5 Years of Follow-up of the Participants in the Study of Men Born in 1913. *Diabetes*. 1985 Oct; 34(10):1055–58. [PubMed: 4043554]
14. IDF. [Retrieved Nov 8, 2015] ONE ADULT IN TEN WILL HAVE DIABETES BY 2030. International Diabetes Federation. 2011. from <http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition>
15. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004 May; 27(5):1047–1053. [Retrieved Nov 21, 2015] from <http://care.diabetesjournals.org/content/27/5/1047.full>. [PubMed: 15111519]
16. ACCORD Research Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *N Engl J Med*. 2008 Jun 12; 358(25):2545–2559. [PubMed: 18539917]
17. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *The Lancet*. 2010 Oct 30; 376(9751)
18. Misawa S, Kuwabara S, Ogawara K, Kitano Y, Yagui K, Hattori T. Hyperglycemia alters refractory periods in human diabetic neuropathy. *Clinical Neurophysiology*. 2004; 115:2525–2529. [Retrieved March 8, 2014] from <http://www.ncbi.nlm.nih.gov/pubmed/15465442>. [PubMed: 15465442]
19. Raffaele Marfella, et al. Acute hyperglycemia induces an oxidative stress in healthy subjects. *J Clin Invest*. 2001; 108(4):635–636. (4). [PubMed: 11518739]
20. Holden SE, Jenkins-Jones S, Morgan CL, Scherthaner G, Currie CJ. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: Dose-response association with all-cause mortality, cardiovascular events, and incident cancer. *Diabetes, Obesity and Metabolism* Volume 17, Issue 4, pages 350–362, April 2015. 2015 Apr; 17(4):350–362.
21. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. *J Clin Endocrinol Metab*. 2013 Feb; 98(2):668–77. [PubMed: 23372169]

22. Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. *Diabetes Care*. 2013 Nov; 36(11):3746–53. [PubMed: 24089540]
23. Redberg RF. Hospital admissions for hypoglycemia now exceed those for hyperglycemia in Medicare beneficiaries. *JAMA Intern Med*. 2014 Jul; 174(7): 1125. 2014 Jul.174(7):1125.
24. Lipska KJ, Ross JS2, Wang Y3, Inzucchi SE1, Minges K4, Karter AJ5, Huang ES6, Desai MM7, Gill TM8, Krumholz HM9. National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. *JAMA Intern Med*. 2014 May 17; 174(7):1116–24. 2014 Jul. [PubMed: 24838229]
25. ADA. Economic costs of diabetes in the In 2007. *Diabetes Care*. 2008 Mar; 31(3):596–615. [Retrieved Nov 18, 2015] from <http://www.ncbi.nlm.nih.gov/pubmed/18308683>. [PubMed: 18308683]
26. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc*. 2003 Dec; 78(12):1471–8. [Retrieved Nov 18, 2015] from <http://www.ncbi.nlm.nih.gov/pubmed/14661676>. [PubMed: 14661676]
27. Flaciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. *Crit Care Med*. 2010; 37(12): 3001–9.
28. González MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Cintrón K, Rodríguez-Gómez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, Vázquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P. Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background. *P R Health Sci J*. 2015 Mar; 34(1):3–8. [PubMed: 25856870]
29. Miranda-Massari JR, González MJ, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Hickey S, Vázquez A, Berdiel MJ, Cintrón K, Rodríguez-Gómez JR. Metabolic Correction: A Functional Biochemical Mechanism Against Disease. Part 2: Mechanisms and Benefits. *P R Health Sci J*. 2015 Mar; 34(1):9–13. [PubMed: 25856871]
30. Bahler L, et al. Role of the autonomic nervous system in activation of human brown adipose tissue: A review of the literature. *Diabetes Metab*. 2015 Dec; 41(6):437–45. [PubMed: 26404650]
31. Mohammed J, Meeus M, Derom E, Da Silva H, Calders P. Evidence for Autonomic Function and Its Influencing Factors in Subjects With COPD: A Systematic Review. *Respir Care*. 2015; 60(12): 1841–51. [PubMed: 26487747]
32. Carnethon MR, et al. Influence of Autonomic Nervous System Dysfunction on the Development of Type 2 Diabetes. *Diabetes Care*. 2003 Nov; 26(11):3035–3041. 2003. [PubMed: 14578236]
33. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. *Am J Hypertens*. 2001 Nov; 14(11 Pt 2):304S–309S. 2001. [PubMed: 11721888]
34. Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Martínez V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve diabetes type 2 management. *P R Health Sci J*. 2015 Mar; 34(1):9–13. [PubMed: 25856871]
35. Unpublished data on file 2015
36. IES. The Health Literacy of America's Adults Results From the 2003 National Assessment of Adult Literacy. U.S. Department of Education. National Center for Education Statistics; 2003. from <https://nces.ed.gov/pubs2006/2006483.pdf> [Retrieved Nov 18, 2015]
37. Herre AJ, Graue M, Kolltveit BC, Gjengedal E. Experience of knowledge and skills that are essential in self-managing a chronic condition - a focus group study among people with type 2 diabetes. *Scand J Caring Sci*. 2016 Jun; 30(2):382–90. [PubMed: 26265512]
38. Breen C, Ryan M, Gibney MJ, O'Shea D. Diabetes-related nutrition knowledge and dietary intake among adults with type 2 diabetes. *Br J Nutr*. 2015; 114(3):439–47. [PubMed: 26169113]
39. Merakou K, Knithaki A, Karageorgos G, Theodoridis D, Barbouni A. Group patient education: effectiveness of a brief intervention in people with type 2 diabetes mellitus in primary health care

- in Greece: a clinically controlled trial. *Health Educ Res.* 2015 Apr; 30(2):223–32. [PubMed: 25724879]
40. Roccella EJ. Potential for reducing health care costs by public and patient education. Summary of selected studies. *Public Health Rep.* 1976 May-Jun;91(3):223–225. [PubMed: 818659]
 41. Elgart JF, González L, Prestes M, Rucci E, Gagliardino JJ. Frequency of self-monitoring blood glucose and attainment of HbA1c target values. *Acta Diabetol.* 2015 Apr 5; 53(1):57–62. 2016 Feb. [PubMed: 25841589]
 42. McIntosh B, Yu C, Lal A, Chelak K, Cameron C, Singh SR, Dahl M. Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. *Open Med.* 2010; 4(2):e102–13. [PubMed: 21686299]
 43. Dailey G. Assessing Glycemic Control With Self-monitoring of Blood Glucose and Hemoglobin A1c Measurements. *Mayo Clinic Proceedings.* 2007 Feb; 82(2):229–236. [PubMed: 17290732]
 44. Schütt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, Mayer I, Rosenbauer J, Wagner C, Zimmermann A, Kerner W, Holl RW. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. *Exp Clin Endocrinol Diabetes.* 2006 Jul; 114(7):384–8. 2006. [PubMed: 16915542]
 45. Nonogaki KIA. Stress, acute hyperglycemia, and hyperlipidemia role of the autonomic nervous system and cytokines. *Trends Endocrinol Metab.* 1997 Jul; 8(5):192–7. [PubMed: 18406806]
 46. Atkinson FS, Foster-Powell K, Brand-Miller JC. International tables of glycemic index and glycemic load values: 2008. *Diabetes Care.* 2008 Dec; 31(12):2281–2283. [PubMed: 18835944]
 47. Pouliot MC, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol.* 1994 Mar 1;73(7). 1994 Mar; 73(7):460–8.
 48. Han TS, et al. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. *BMJ.* 1995 Nov 25; 311(7017):1401–5. [PubMed: 8520275]
 49. Wu S, Wang R, Jiang A, Ding Y, Wu M, Ma X, Zhao Y, He J. Abdominal obesity and its association with health-related quality of life in adults: a population-based study in five Chinese cities. *Health Qual Life Outcomes.* 2014 Jun.13(12)
 50. Deedwania PC. Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. *Am J Cardiol.* 2003; 91(1):68–71. [PubMed: 12505574]
 51. Milicevic Z, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. *Diabetes Care.* 2008 Feb; 31(Suppl 2):S155–60. [PubMed: 18227478]
 52. Niefeld MR, et al. Preventable hospitalization among elderly Medicare beneficiaries with type 2 diabetes. *Diabetes Care.* 2003 May; 26(5):1344–9. [PubMed: 12716786]
 53. Feldstein AC, et al. Weight change in diabetes and glycemic and blood pressure control. *Diabetes Care.* 2008 Oct; 31(10):1960–5. [PubMed: 18697899]
 54. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. *Diabetes Obes Metab.* 2010 Mar; 12(3):186–94. [PubMed: 20151995]
 55. Davis WA, Bruce DG, Davis TM. Economic impact of moderate weight loss in patients with Type 2 diabetes: the Fremantle Diabetes Study. *Diabet Med.* 2011 Sep; 28(9):1131–5. [PubMed: 21843308]
 56. Yu AP, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. *Curr Med Res Opin.* 2007 Sep; 23(9):2157–69. [PubMed: 17669232]
 57. CDC. NHANES 2005–2006. National Center for Health Statistics; 2008. from http://wwwn.cdc.gov/nchs/nhanes/search/nhanes05_06.aspx [Retrieved Nov 21, 2015]
 58. Krebs-Smith SM. Americans do not meet federal dietary recommendations. *J Nutr.* 2010 Oct; 140(10):1832–8. [PubMed: 20702750]
 59. Nadler JL, et al. Intracellular Free Magnesium Deficiency Plays a Key Role in Increased Platelet Reactivity in Type II Diabetes Mellitus. *Diabetes Care.* 1992 Jul; 15(7):835–841. [PubMed: 1516501]
 60. de Valk HW. Magnesium in diabetes mellitus. *Neth J Med.* 1999 Apr; 54(4):139–46. [PubMed: 10218382]

61. Sales CH, Pedrosa L, de F. Magnesium and diabetes mellitus: their relation. *Clin Nutr.* 2006 Aug; 25(4):554–62. [PubMed: 16690176]
62. Barbagallo MDL. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. *Arch Biochem Biophys.* 2007 Feb 1; 458(1):40–7. [PubMed: 16808892]
63. Chaudhary DP, et al. Implications of magnesium deficiency in type 2 diabetes: a review. *Biol Trace Elem Res.* 2010 May; 134(2):119–29. [PubMed: 19629403]
64. Jahnen-Dechent, WKM. [Retrieved Feb 10, 2014] Magnesium basics. *CKJ Oxford Journal.* 2012. from http://m.ckj.oxfordjournals.org/content/5/Suppl_1/i3.full
65. Thomson CA, et al. Relationship between sleep quality and quantity and weight loss in women participating in a weight-loss intervention trial. *Obesity.* 2012 Jul; 20(7):1419–25. [Retrieved Jan 15, 2015] from <http://www.ncbi.nlm.nih.gov/pubmed/22402738>. [PubMed: 22402738]
66. Rodríguez-Morán M, et al. Oral Magnesium Supplementation Improves Insulin Sensitivity and Metabolic Control in Type 2 Diabetic Subjects. *Diabetes Care.* 2003 Apr; 26(4):1147–1152. [PubMed: 12663588]
67. Ip M, M Da, Mokhlesi B. Sleep and Glucose Intolerance/Diabetes Mellitus. *Sleep Med Clin.* 2007; 2(1):19–29. DOI: 10.1016/j.jsmc.2006.12.002 [PubMed: 19536352]
68. Taddei SPR. Sympathetic nervous system-dependent vasoconstriction in humans. Evidence for mechanistic role of endogenous purine compounds. *Circulation.* 1990 Dec; 82(6):2061–7. [PubMed: 1978700]
69. Abbasi BKM. The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. *J Res Med Sci.* 2012 Dec; 17(12):1161–9. [PubMed: 23853635]
70. Spiegel K, et al. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. *Journal of Applied Physiology.* 2005 Nov 1; 99(5):2008–2019. [PubMed: 16227462]
71. Gottlieb DJ, et al. Association of Sleep Time With Diabetes Mellitus and Impaired Glucose Tolerance. *Arch Intern Med.* 2005; 165(8):863–867. [PubMed: 15851636]
72. Knutson KL, et al. Cross-Sectional Associations Between Measures of Sleep and Markers of Glucose Metabolism Among Subjects With and Without Diabetes. *Diabetes Care.* 2011 May; 34(5):1171–1176. [PubMed: 21411507]
73. Ma JFA. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. *Atherosclerosis Risk in Communities Study. J Clin Epidemiol.* 1995 Jul; 48(7):927–40. [PubMed: 7782801]
74. Resnick LM, G R. Hypertension and peripheral insulin resistance. Possible mediating role of intracellular free magnesium. *Am J Hypertens.* 1990 May; 3(5 Pt 1):373–9. [PubMed: 2190608]
75. Houston M. The role of magnesium in hypertension and cardiovascular disease. *J Clin Hypertens (Greenwich).* 2011 Nov; 13(11):843–7. [PubMed: 22051430]
76. Yokota KKM. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. *J Am Coll Nutr.* 2004 Oct; 23(5):506S–509S. [PubMed: 15466952]
77. Swaminathan R. Magnesium Metabolism and its Disorders. *Clin Biochem Rev.* 2003 May; 24(2): 47–66. [PubMed: 18568054]
78. Rosolová HMO. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. *Metabolism.* 2000; 49(3):418–20. [PubMed: 10726923]
79. Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). *Clin Biochem.* 2001 Oct; 34(7):583–8. [PubMed: 11738396]
80. Lamarche B, et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). *Am J Cardiol.* 1995 Jun; 15(75):1189–95.
81. Carr MC, Brunzell JD. Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk. *Clinical Endocrinology & Metabolism.* 2004; 89(6):2601–2607.
82. Aude YW, et al. The National Cholesterol Education Program Diet vs a Diet Lower in Carbohydrates and Higher in Protein and Monounsaturated Fat. *JAMA Internal Medicine.* 2004 Oct 25; 164(19):2141–2146. DOI: 10.1001/archinte.164.19.2141

83. Shai I, et al. Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet. *N Engl J Med*. 2008; 359:229–241. DOI: 10.1056/NEJMoa0708681 [PubMed: 18635428]
84. Hite AH, et al. Low-Carbohydrate Diet Review: Shifting the Paradigm. *Nutrition in Clinical Practice*. 2011 Jun; 26(3):300–308. DOI: 10.1177/0884533611405791 [PubMed: 21586415]
85. Accurso ABR. Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. *Nutr Metab (Lond)*. 2008; 5:9. [PubMed: 18397522]
86. Nielsen JV, J E. Lasting improvements of hyperglycemia and bodyweight: low-carbohydrate diet in type 2 diabetes. *Ups J Med Sci*. 2005; 110(2):179–83. [PubMed: 16075898]
87. Bouché C, et al. Five-week, low-glycemic index diet decreases total fat mass and improves plasma lipid profile in moderately overweight nondiabetic men. *Diabetes Care*. 2002 May; 25(5):822–8. [PubMed: 11978675]
88. Goff LM, et al. Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials. *Nutr Metab Cardiovasc Dis*. 2013 Jan; 23(1):1–10. [PubMed: 22841185]
89. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. *Arch Intern Med*. 1995 Oct 9; 155(18):1949–56. [PubMed: 7575048]
90. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. *J Am Pharm Assoc (Wash)*. 2001 Mar-Apr;41(2):192–9. [PubMed: 11297331]

labs and anthropometrics over 6 months period




Figure 1.
Labs and anthropometrics over 6 months period in MRT-MD protocol

change in atherogenic index and glycosilated hemoglobin A1c




Figure 2.
Atherogenic Index and Glycosilated hemoglobin over 6 months period

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3.
Monthly Medication Cost Reduction per patient over 6 month

Table 1

Changes in Medication Monthly Costs in Study Group

PATIENTS USING	AT START	AT 3 MONTHS	AT 6 MONTHS
50	\$7,729.12	\$5,331.61	\$4,521.29
MEDICATION SAVINGS % from Baseline →		-31.0%	-41.5%
MONTHLY SAVINGS PER PATIENT →		\$47.95	\$64.16
PROYECTED YEARLY SAVINGS PER PATIENT →		\$575.40	\$ 769.92
PROYECTED YEARLY SAVINGS IN ALL MEDICATIONS FOR ALL PARTICIPANTS →		\$28,770.00	\$ 38,496.00

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Pairwise Comparisons^a

MEASURE-1 (Cost Reduction in Diabetes medications -Oral medication and insulin)						
Time Period (I)	Time Period (J)	Mean Difference (I-J)	Std. Error	Sig. ^b	95% Confidence Interval for Difference ^b	
					Lower Bound	Upper Bound
1	2	45.571 *	17.007	.030	3.411	87.732
	3	96.475 *	32.647	.014	15.545	177.406
2	1	-45.571 *	17.007	.030	-87.732	-3.411
	3	50.904	24.877	.138	-10.764	112.572

^a . Based on estimated marginal means

*. The mean difference is significant at p<.05

^b . Adjustment for multiple comparisons: Bonferroni.

Table 3

Pairwise Comparisons^a

MEASURE-1 (Cost Reduction in non diabetic medications)						
(I) ND-Period	(J) ND-Period	Mean Difference (I-J)	Std. Error	Sig. ^b	95% Confidence Interval for Difference ^b	
					Lower Bound	Upper Bound
1	2	3.231	1.371	.068	-.168	6.630
	3	3.786*	1.417	.031	.274	7.298
2	1	-3.231	1.371	.068	-6.630	.168
	3	.555	.447	.662	-.554	1.664

^a . Based on estimated marginal means

* The mean difference is significant at the P<.05

^b . Adjustment for multiple comparisons: Bonferroni.